Chennai based Bioneemtec India has received support from Technology Development Board for commercializing indigenous green chemistry technologies to produce critical pharmaceutical ingredients
The Technology Development Board (TDB), Department of Science & Technology (DST), Government of India, has extended support to Bioneemtec India Private Limited, Chennaifor commercializing indigenous green chemistry technologies for the production of critical pharmaceutical ingredients and advanced drug delivery systems.
The project titled ‘Manufacturing of Minoxidil, Tranexamic Acid, Dequalinium Chloride, their Intermediates and Drug Liposomes’ seeks tocontributing to import substitution, sustainable manufacturing, and healthcare security.
The project focuses on establishing advanced manufacturing capabilities for pharmaceutical intermediates, Active Pharmaceutical Ingredients (APIs), and novel drug delivery systems through a combination of batch and continuous-flow chemistry technologies.
A key component of the project is the commercialization of an indigenous process for manufacturing Tranexamic Acid, an important therapeutic molecule used in the management of bleeding disorders. Developed using a cost-effective and environmentally responsible synthesis route, the technology is designed to deliver high-purity products while minimizing waste generation and process complexity.
The project will also support the domestic production of Minoxidil and Dequalinium Chloride along with their key intermediates, strengthening local manufacturing capabilities in pharmaceutical value chains that presently depend substantially on imports.
Bioneemtec has developed proprietary Drug Liposome APIs based on advanced nanotechnology platforms. These liposomal formulations are being developed for therapeutic applications including breast and skin cancer management and have demonstrated promising results with controlled nanoparticle characteristics.
Rajesh Kumar Pathak, Secretary, TDB, stated, “The future of pharmaceutical manufacturing lies in sustainable, technology-driven production systems that combine quality, efficiency, and environmental responsibility. Indigenous development of advanced APIs, critical intermediates, and novel drug delivery platforms will be instrumental in strengthening India’s position as a global pharmaceutical manufacturing hub.”
“TDB is committed to supporting such innovative enterprises that are creating high-value technologies while contributing to import substitution and healthcare security,” added Pathak.
Expressing gratitude for the support, the leadership of Bioneemtec India Private Limited stated that the project will enable the company to scale up commercialization of its green chemistry-based manufacturing technologies and advanced pharmaceutical products.
Lonza and Stipple Bio partner to advance next-generation precision oncology ADC therapies
Aurobindo Pharma receives USFDA nod for generic Tofacitinib tablets
Suven Life reports positive interim review for phase 3 Alzheimer’s therapy
Kaushik Deb elevated to Vice President at Mankind Pharma
CBC India partners with Metalco-Alupack to strengthen pharma aluminium packaging solutions
Subscribe To Our Newsletter & Stay Updated
Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants
Implementing a digital transformation in chemical operations to maximize profitability
The complexity of compliance
The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation
The guiding role of fluidized and spouted bed technologies in particle building processes
Indian Pharma Post is an online platform that provides news and insights on the pharmaceutical industry. It reports on the latest news updates, drug discoveries, and research reports. It highlights trending topics in the entire healthcare universe and will lay emphasis on the new best practices across the spectrum of the industry.
It houses a team of experts who will provide insights on policies that shape developments in the industry.
Get Indian Pharma Post News‘s top stories every morning in your email inbox.
Follow @Indian Pharma Post for the latest news, insider access to events and more.
Copyright © 2026 Indian Pharma Post. All Rights Reserved.
Subscribe To Our Newsletter & Stay Updated
Leave a Reply